WO2001085789A3 - Extracellular domain of ryk protein for regulating angiogenesis - Google Patents

Extracellular domain of ryk protein for regulating angiogenesis Download PDF

Info

Publication number
WO2001085789A3
WO2001085789A3 PCT/US2001/015043 US0115043W WO0185789A3 WO 2001085789 A3 WO2001085789 A3 WO 2001085789A3 US 0115043 W US0115043 W US 0115043W WO 0185789 A3 WO0185789 A3 WO 0185789A3
Authority
WO
WIPO (PCT)
Prior art keywords
ryk
extracellular domain
diseases
regulating angiogenesis
angiogenesis
Prior art date
Application number
PCT/US2001/015043
Other languages
French (fr)
Other versions
WO2001085789A2 (en
Inventor
Steve Roczniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Original Assignee
Bayer Ag
Steve Roczniak
Dubois Stringfellow Nathalie A
Alya Zolotorev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Steve Roczniak, Dubois Stringfellow Nathalie A, Alya Zolotorev filed Critical Bayer Ag
Priority to EP01935233A priority Critical patent/EP1287121A2/en
Priority to CA002408349A priority patent/CA2408349A1/en
Priority to US10/275,589 priority patent/US20040023864A1/en
Priority to JP2001582388A priority patent/JP2004527206A/en
Priority to AU2001261343A priority patent/AU2001261343A1/en
Publication of WO2001085789A2 publication Critical patent/WO2001085789A2/en
Publication of WO2001085789A3 publication Critical patent/WO2001085789A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ryk protein was found to have a novel activity in regulating angiogenesis. New variant Ryk proteins were constructed that were useful in modulating the capillary forming activity of endothelial cells. Variant Ryk proteins, may be employed as therapeutics in diseases such as cancer, wound healing, diabetic retinopathies, macular degeneration, and cardiovascular diseases, and other diseases or clinical conditions where angiogenesis is relevant to the causation or treatment of the disease.
PCT/US2001/015043 2000-05-10 2001-05-09 Extracellular domain of ryk protein for regulating angiogenesis WO2001085789A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01935233A EP1287121A2 (en) 2000-05-10 2001-05-09 Extracellular domain of ryk protein for regulating angiogenesis
CA002408349A CA2408349A1 (en) 2000-05-10 2001-05-09 Method of regulating angiogenesis unsing ryk protein
US10/275,589 US20040023864A1 (en) 2001-05-09 2001-05-09 Method of regulating angiogenesis using ryk protein
JP2001582388A JP2004527206A (en) 2000-05-10 2001-05-09 Method for regulating angiogenesis using Ryk protein
AU2001261343A AU2001261343A1 (en) 2000-05-10 2001-05-09 Method of regulating angiogenesis using ryk protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10
US09/568,783 2000-05-10

Publications (2)

Publication Number Publication Date
WO2001085789A2 WO2001085789A2 (en) 2001-11-15
WO2001085789A3 true WO2001085789A3 (en) 2002-05-16

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015043 WO2001085789A2 (en) 2000-05-10 2001-05-09 Extracellular domain of ryk protein for regulating angiogenesis

Country Status (13)

Country Link
EP (1) EP1287121A2 (en)
JP (1) JP2004527206A (en)
AR (1) AR028424A1 (en)
AU (1) AU2001261343A1 (en)
CA (1) CA2408349A1 (en)
CO (1) CO5300464A1 (en)
DO (1) DOP2001000164A (en)
EC (1) ECSP014068A (en)
GT (1) GT200100079A (en)
PE (1) PE20011218A1 (en)
SV (1) SV2002000442A (en)
UY (1) UY26696A1 (en)
WO (1) WO2001085789A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471934A2 (en) * 2002-02-06 2004-11-03 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
TR201909951T4 (en) 2014-07-18 2019-07-22 Sanofi Sa A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023429A1 (en) * 1992-05-11 1993-11-25 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
EP0854185A2 (en) * 1994-12-23 1998-07-22 Ludwig Institute For Cancer Research Assay receptor proteins and ligands
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023429A1 (en) * 1992-05-11 1993-11-25 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
EP0854185A2 (en) * 1994-12-23 1998-07-22 Ludwig Institute For Cancer Research Assay receptor proteins and ligands
WO1999064589A1 (en) * 1998-06-11 1999-12-16 Astrazeneca Ab Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HALFORD MICHAEL M ET AL: "Genomic structure and expression of the mouse growth factor receptor related to tyrosine kinases (Ryk).", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 11, 12 March 1999 (1999-03-12), pages 7379 - 7390, XP002189270, ISSN: 0021-9258 *
SHAWVER ET AL: "Receptor tyrosine kinases as targets for inhibition of angiogenesis", DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 2, no. 2, February 1997 (1997-02-01), pages 50 - 63, XP002118090, ISSN: 1359-6446 *
TAMAGNONE LUCA ET AL: "The human ryk cDNA sequence predicts a protein containing two putative transmembrane segments and a tyrosine kinase catalytic domain.", ONCOGENE, vol. 8, no. 7, 1993, pages 2009 - 2014, XP002189269, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
WO2001085789A2 (en) 2001-11-15
PE20011218A1 (en) 2002-02-01
UY26696A1 (en) 2001-12-28
EP1287121A2 (en) 2003-03-05
ECSP014068A (en) 2002-02-25
GT200100079A (en) 2001-12-31
SV2002000442A (en) 2002-07-03
JP2004527206A (en) 2004-09-09
AU2001261343A1 (en) 2001-11-20
AR028424A1 (en) 2003-05-07
CO5300464A1 (en) 2003-07-31
CA2408349A1 (en) 2001-11-15
DOP2001000164A (en) 2002-05-15

Similar Documents

Publication Publication Date Title
Kornblatt et al. The neglected role of copper ions in wound healing
ATE290401T1 (en) TOPICAL AGENTS FOR NAIL FUNGUS DISEASES
RS30104A (en) Keratinocytes which may be used as a biologically active substance in the treatment of wounds
WO2004110472A3 (en) Fusion proteins
HUP0100178A2 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
DE69812151D1 (en) LACTIC ACID BACTERIA CONTAINING PRODUCT AND PRODUCTION
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
PT749317E (en) THERAPEUTIC APPLICATIONS OF DIMERIC PRODUCTS OF PERMEABILITY INDUCED BACTERICID PROTEINS
DE69931907D1 (en) HAGA BUTTER COMPOSITIONS AS AN ANTI-INFLAMMABLE NATURAL MEDICAMENT TO FACILITATE / REDUCE SYMPTOMS RELATING TO INFLAMMATION AND ARTHRITIS
WO2005012492A3 (en) Human skin equivalents expressing exogenous polypeptides
NO971341D0 (en) Promoter for receptor tyrosine kinase TIE
WO2003031407A3 (en) β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
EP1172084A3 (en) Cosmetic and dermatologic composition to eliminate sebum
WO2001085789A3 (en) Extracellular domain of ryk protein for regulating angiogenesis
DE602005020178D1 (en) 5,6,7-TRIHYDROXYPHEPTANIC ACIDS AND ANALOGS FOR THE TREATMENT OF EYE DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVES AND ANGIOGENIC REACTIONS
AU7538700A (en) 5-hydroxysapogenin derivatives with anti-dementia activity
WO2001044294A3 (en) Compositions and methods for inhibiting endothelial cell proliferation
WO2001045738A3 (en) Use of heat shock proteins to enhance production of chemokines by a cell
WO2001074852A3 (en) Protein having activity as an angiogenesis modulator
DE60107444D1 (en) USE OF A POLLEN EXTRACT CONTAINER FOR THE TREATMENT OF EDEMS
WO2001036462A3 (en) Protein c derivatives
WO2003000222A3 (en) Cosmetic preparation with anti-wrinkle action
FR2835429B1 (en) USE OF ASCORBIC ACID TO STRENGTHEN COHESION OF THE DERMO-EPIDERMAL JUNCTION
ATE222501T1 (en) TISSUE FACTOR INFLUENCING VASCULAR FORMATION
WO2001070948A3 (en) Methods and compositions for elucidating protein expression profiles in cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2408349

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001935233

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001935233

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10275589

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001935233

Country of ref document: EP